259 related articles for article (PubMed ID: 11440031)
1. 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study.
Tiling R; Linke R; Untch M; Richter A; Fieber S; Brinkbäumer K; Tatsch K; Hahn K
Eur J Nucl Med; 2001 Jun; 28(6):711-20. PubMed ID: 11440031
[TBL] [Abstract][Full Text] [Related]
2. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
[TBL] [Abstract][Full Text] [Related]
3. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours.
Palmedo H; Bender H; Grünwald F; Mallmann P; Zamora P; Krebs D; Biersack HJ
Eur J Nucl Med; 1997 Sep; 24(9):1138-45. PubMed ID: 9283107
[TBL] [Abstract][Full Text] [Related]
4. 11C-acetate PET imaging of lung cancer: comparison with 18F-FDG PET and 99mTc-MIBI SPET.
Higashi K; Ueda Y; Matsunari I; Kodama Y; Ikeda R; Miura K; Taki S; Higuchi T; Tonami H; Yamamoto I
Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):13-21. PubMed ID: 14574513
[TBL] [Abstract][Full Text] [Related]
5. Is Technetium-99m Sestamibi Imaging Able to Predict Pathologic Nonresponse to Neoadjuvant Chemotherapy in Breast Cancer? A Meta-analysis Evaluating Current Use and Shortcomings.
Collarino A; de Koster EJ; Valdés Olmos RA; de Geus-Oei LF; Pereira Arias-Bouda LM
Clin Breast Cancer; 2018 Feb; 18(1):9-18. PubMed ID: 28728876
[TBL] [Abstract][Full Text] [Related]
6. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer: monitoring response to neoadjuvant chemotherapy using Tc-99m sestamibi scintimammography.
Tiling R; Kessler M; Untch M; Sommer H; Linke R; Brinkbäumer K; Hahn K
Onkologie; 2003 Feb; 26(1):27-31. PubMed ID: 12624514
[TBL] [Abstract][Full Text] [Related]
8. In vivo detection of resistance to anthracycline based neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer with technetium-99m sestamibi scintimammography.
Mezi S; Primi F; Capoccetti F; Scopinaro F; Modesti M; Schillaci O
Int J Oncol; 2003 Jun; 22(6):1233-40. PubMed ID: 12738988
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography.
Mankoff DA; Dunnwald LK; Gralow JR; Ellis GK; Drucker MJ; Livingston RB
Cancer; 1999 Jun; 85(11):2410-23. PubMed ID: 10357412
[TBL] [Abstract][Full Text] [Related]
11. Myocardial distribution of (18)F-FDG and (99m)Tc-sestamibi on dual-isotope simultaneous acquisition SPET compared with PET.
Matsunari I; Kanayama S; Yoneyama T; Matsudaira M; Nakajima K; Taki J; Nekolla SG; Takekoshi N; Tonami N; Hisada K
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1357-64. PubMed ID: 12271419
[TBL] [Abstract][Full Text] [Related]
12. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
[TBL] [Abstract][Full Text] [Related]
13. [Breast scintigraphy using 99mTc-sestamibi--use and limitations].
Tiling R; Linke R; Kessler M; Untch M; Sommer H; Brinkbäumer K; Becker I; Hahn K
Nuklearmedizin; 2002 Jun; 41(3):148-56. PubMed ID: 12109035
[TBL] [Abstract][Full Text] [Related]
14. 99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients.
Sergieva SB; Timcheva KV; Hadjiolov ND
J BUON; 2006; 11(1):61-8. PubMed ID: 17318954
[TBL] [Abstract][Full Text] [Related]
15. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
Dose-Schwarz J; Tiling R; Avril-Sassen S; Mahner S; Lebeau A; Weber C; Schwaiger M; Jänicke F; Untch M; Avril N
Br J Cancer; 2010 Jan; 102(1):35-41. PubMed ID: 19920815
[TBL] [Abstract][Full Text] [Related]
16. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
[TBL] [Abstract][Full Text] [Related]
17. Is Tc-99m sestamibi scintimammography useful in the prediction of neoadjuvant chemotherapy responses in breast cancer? A systematic review and meta-analysis.
Guo C; Zhang C; Liu J; Tong L; Huang G
Nucl Med Commun; 2016 Jul; 37(7):675-88. PubMed ID: 26974314
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy.
Bader JB; Samnick S; Moringlane JR; Feiden W; Schaefer A; Kremp S; Kirsch CM
Eur J Nucl Med; 1999 Feb; 26(2):144-51. PubMed ID: 9933348
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment evaluation of carcinomas of the hypopharynx and larynx with 18F-fluorodeoxyglucose, 123I-alpha-methyl-L-tyrosine and 99mTc-hexakis-2-methoxyisobutylisonitrile.
Henze M; Mohammed A; Mier W; Rudat V; Dietz A; Nollert J; Eisenhut M; Haberkorn U
Eur J Nucl Med Mol Imaging; 2002 Mar; 29(3):324-30. PubMed ID: 12002706
[TBL] [Abstract][Full Text] [Related]
20. Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival.
Dunnwald LK; Gralow JR; Ellis GK; Livingston RB; Linden HM; Lawton TJ; Barlow WE; Schubert EK; Mankoff DA
Cancer; 2005 Feb; 103(4):680-8. PubMed ID: 15637688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
